2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 10

Autoantibodies Targeting Domain 1 Of Beta 2 Glycoprotein I As Promising Marker In The Diagnosis and Risk Stratification Of The Antiphospholipid Syndrome
Abstract Number: 1327

Autoantibodies To Citrullinated Proteins Associate With Bone Destruction Marker and Are Modulated By First Anti Rheumatic Treatment In Early Rheumatoid Arthritis
Abstract Number: 1748

Autoantibodies To RuvBL1 and RuvBL2: A Novel Systemic Sclerosis-Related Antibody Associated With Diffuse Cutaneous and Skeletal Muscle Involvement
Abstract Number: 926

Autoantibodies to the Th/To Complex Are the Most Common Antibodies in Systemic Sclerosis (SSc) Patients Without Other Autoantibodies
Abstract Number: 1602

Autoantibodies, Cytokines and Chemokines In Serum and Cerebrospinal Fluid Of SLE Patients With Cognitive Dysfunction
Abstract Number: 671

Autoantibody Diversity In Scleroderma Patients With Antinucleolar Antibodies and Negative For Three Major Disease-Specific Markers
Abstract Number: 494

Autoantibody Profiles Predict Responsiveness To Methotrexate and Anti-TNF Therapy In Early Rheumatoid Arthritis
Abstract Number: 1884

Autoantibody Specificities and Type I Interferon Pathway Activation In Idiopathic Inflammatory Myopathies
Abstract Number: 2862

Autoantigen Microarray Analysis Of Sera From New-Onset Pediatric Systemic Lupus Erythematosus Patients: A Distinct Autoantibody Profile Associated With Class III/IV Lupus Nephritis
Abstract Number: 1148

Autologous Tolerogenic Dendritic Cells In Rheumatoid and Inflammatory Arthritis
Abstract Number: 1818

Automated Telephone-Linked Communication: A Novel Approach To Enhance Long-Term Adherence To Resistance Training Exercise Among People With Knee Osteoarthritis
Abstract Number: 390

Autonomic Dysfunction In Rheumatoid Arthritis Improves With Disease Modifying Anti Rheumatic Drugs
Abstract Number: 1597

Autonomic Dysfunction In Systemic Lupus Erythematosus Patients With Previous Neuropsychiatric Involvement
Abstract Number: 145

Autonomic Nervous System “Decomplexification” In Fibromyalgia. A Proof Of Concept Study Looking At The Fractality Of Heart Rhythms
Abstract Number: 68

Autophagy Activation Protects From Mitochondrial Dysfunction In Human Chondrocytes

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].